NL-OMON35436已完成不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND THE EFFECT OF FOOD AND KETOCONAZOLE ON THE PHARMACOKINETICS OF IPI-145 WHEN ADMINISTERED TO HEALTHY ADULT SUBJECTS - IPI-145 SAD/MAD/FE/DDI study
Infinity Pharmaceuticals0 个研究点目标入组 106 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age: 18 * 55 years, inclusive
- •BMI: 18.0 * 30.0 kg/m2, inclusive
排除标准
- •Suffering from: hepatitis B, C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1.5 liter (for men)/ 1.0 liter (for women) of blood in the 10 months prior the start of this study.
研究者
相似试验
招募中
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE ASCENDING DOSE TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LEO 158968 IN HEALTHY SUBJECTSNL-OMON53439eo Pharma120
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC AND FOOD EFFECT OF BCI 838 AND AN OPEN-LABEL MINIDOSE BIOAVAILABILITY STUDY TO COMPARE SEVERAL BCI-632 PRO-DRUG CANDIDATES IN HEALTHY MALE SUBJECTSdepressionmood disorders10027946NL-OMON35311BrainCells Inc.30
已完成
4 期
A clinical study to assess the benefits of Concentrace Trace Mineral Drops-(CTMD®), a food supplement in subjects with OSTEOARTHRITIS (OA) of knee jointCTRI/2010/091/001105Dr. Himanshu Bansal100
已完成
2 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUStype 2 diabetes mellitus10012653diabetesNL-OMON34301Hanmi Pharmaceutical Company Ltd48
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS - HM11260C SAD study in patients with type 2 diabetes mellitustype 2 diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2010-019665-28-NLHanmi Pharmaceutical Company Limited